Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 3, 2008, Pages 116-121

  Shimano, Hitoshi ^a,b   Arai, Hidenori ^a   Harada Shiba, Mariko ^a   Ueshima, Hirotsugu ^a   Ohta, Takao ^a   Yamashita, Shizuya ^a   Gotoda, Takanari ^a   Kiyohara, Yutaka ^a   Hayashi, Toshio ^a   Kobayashi, Junji ^a   Shimamoto, Kazuaki ^a   Bujo, Hideaki ^a   Ishibashi, Shun ^a   Shirai, Koji ^a   Oikawa, Shinichi ^a   Saito, Yasushi ^a   Yamada, Nobuhiro ^a  

^a Ministry for Health Labor and Welfare in Japan   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Dyslipidemia; HDL cholesterol; Hyperlipidemia; LDL cholesterol; Triglycerides

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR DISEASE; CHEMISTRY; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; JAPAN; METABOLISM; PATHOLOGY; PRACTICE GUIDELINE; RISK FACTOR; STANDARD;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; GUIDELINES AS TOPIC; HUMANS; HYPERTRIGLYCERIDEMIA; JAPAN; LIPIDS; RISK FACTORS;

EID: 48849108904     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E560     Document Type: Article

References (25)

1. Assmann G, Schulte H, Funke H, and von Eckardstein A: The emergence of triglycerides as a significant independent risk Factor in coronary artery disease, Eur Heart J, 1998; 19 Suppl MM8-14
2. Austin MA, Hokanson JE, and Edwards KL: Hypertriglyceridemia as a cardiovascular risk Factor, Am J Cardiol, 1998; 81:7B-12B
3. Krauss RM: Atherogenicity of triglyceride-rich lipoproteins, Am J Cardiol, 1998; 81:13B-17B
4. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome, Am J Cardiol, 1998; 81:18B-25B
5. Havel RJ: Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation, 1990; 81:694-696
6. Breslow JL: Mouse models of atherosclerosis. Science, 1996; 272:685-688
7. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, and Feher MD: Cardiovascular outcomes in type 2 diabetes, A double-blind placebo-controlled study of bezafibrate. the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Stud. Diabetes Care, 1998; 21:641-648
8. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, and Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med, 2005; 165: 1154-1160
9. Keech A. Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, and Laakso M: Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366:l849-1861
10. Grundy SM: Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target, Arch Intern Med, 2001; 161:1379-1380
11. Packard CJ and Saito Y: Non-HDL cholesterol as a measure of atherosclerotic risk, J Atheroscler Thromb, 2004; 11:6-14
12. Liu J, Sempos CT, Donahue RE Dorn J, Trevisan M, and Grundy SM: Non-high-dcrisity lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease, Am J Cardiol, 2006; 98:1363-1368
13. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, and Rimm EB: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation, 2005; 112:3375-3383
14. Kawamoto R, Oka Y, Tomita H, and Kodama A: Non-HDL cholesterol as a predictor of carotid atherosclerosis. in the elderly. J Atheroscler Thromb, 2005; 12:143-448
15. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, and Hu FB: Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care, 2DO4; 27:1991-1997
16. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, and Inaba M: Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl, 2003; 84:S117-120
17. Frost PH and Havel RJ: Rationale for use of non-high-density, lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol, 1998; 81:26B-31B
18. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, and Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 2001; 161:1413-1419
19. Vega GL and Grundy SM: Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis, 1990; 10:668-671
20. Simon A, Chironi G. Gariepy J, Del Pino M, and Levenson J: Differences between markers of atherogenic lipoprootein in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 2005; 179:339-344
21. Sugimoto K, Isobe K, Kawakami Y, and Yamada N: The relationship between non-HDL cholesterol and other lipid parameters in-Japanese subjects. J Atheroscler Thromb, 2005; 12:107-110
22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106; 3143-3421
23. Goldstein JL, Schrott HG, Hazzard WT, Bierman EL, and Motulsky AG: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined, hyperlipidemia. J Clin Invest, 1973; 52:1544-1568
24. Heiss G, Tamir I, Davis CE: Tyroler HA, Rifkand BM, Schonfeld G. Jacobs D, and Frantz ID Jr.: Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation, 1980; 61:302-315
25. Yokoyama M, Origasa. H, Matsuzaki,.M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, and Shirato K: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded end-point analysis. Lancet, 2007; 369:1090-1098